In-Vitro activities of tetracyclines, macrolides, fluoroquinolones and clindamycin against Mycoplasma hominis and Ureaplasma ssp. isolated in Germany over 20 years  by Krausse, R. & Schubert, S.
In-Vitro activities of tetracyclines, macrolides, ﬂuoroquinolones and
clindamycin against Mycoplasma hominis and Ureaplasma ssp. isolated
in Germany over 20 years
R. Krausse and S. Schubert
Institute for Infection Medicine, University Medical Center Schleswig-Holstein Campus Kiel, and Christian Albrecht University of Kiel, Germany
Abstract
Antimicrobial resistance in genital mycoplasmas is increasing and shows global variation. We determined the susceptibilities of 469
mycoplamas, comprising 290 Mycoplasma hominis and 179 ureaplasma isolates collected during 1983 and 1989–2004, to eleven antibac-
terials by agar dilution. Additionally, we analyzed the results of routine E-testing during 2005–2008. Doxycycline was the most active
tetracycline with (MIC90 of 1 and 8 mg/L for ureaplasmas and M. hominis, respectively. Signiﬁcantly more M. hominis isolates (approxi-
mately 10–13%) than ureaplasmas (approximately 1–3%) were resistant to tetracyclines. Oﬂoxacin was effective against both species
(>95% susceptibility). Ciproﬂoxacin was moderately active against M. hominis and less active against ureaplasmas (70.3% and 35.2% sus-
ceptibility, respectively). Clarithromycin and josamycin were the most potent macrolides (MIC90 of 0.5 mg/L) against ureaplasmas.
Erythromycin had the lowest activity (MIC90 of 8 mg/L) against ureaplasmas like clindamycin which was the most potent agent against
M. hominis. Cross-resistance was found between tetracyclines (53–93%), macrolides and erythromycin (70–100%), and between eryth-
romycin and ciproﬂoxacin (43–55%). M. hominis became more resistant to tetracyclines and ﬂuoroquinolones between 1989 and 2004,
although there was little change during 2005–2008. Ureaplasmas became more resistant to cipﬂoxacin during 1997 – 2004 and showed
high resistance rates to erythromycin during 1989 – 2008. Doxycycline is still the drug of ﬁrst-choice for the treatment of ureaplasmal
infections and may be used for co-infection with M. hominis.
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Introduction
Mycoplasma hominis and ureaplasmas frequently colonize the
genital tract of humans. They are associated with genitouri-
nary tract infections (urethritis, cervicitis, cystitis, bacterial
vaginosis) and appear to have an aetiological role in postpar-
tum infections of mothers and newborns [1–5].
Mycoplasma and Ureaplasma spp. are susceptible to agents
that interfere with protein synthesis, such as tetracycline,
macrolides, aminoglycosides and chloramphenicol, and to the
ﬂuoroquinolones that act by inhibiting topoisomerases
[4,6–12]. Mycoplasma and ureaplasma infections are usually
treated with tetracycline, except in pregnant women, neo-
nates or children in whom erythromycin is recommended
[4,10,11]. However, there are increasing reports of resis-
tance to these agents as a result of the presence of the tetM
resistance determinant or chromosomal mutation [10,11,13–
17]. Clindamycin, ﬂuoroquinolones or other macrolides
can be used to treat infections that do not respond to tetra-
cycline or erythromycin [9,10]. However, there are few large
studies on the antimicrobial susceptibilities of these species.
The purpose of the present study was: (i) to investigate
the susceptibilities of a large number of clinical isolates of
M. hominis and ureaplasmas to various antimicrobial agents,
including tetracyclines, macrolides, clindamycin and ﬂouroqui-
nolones, and (ii) to compare changes in the antimicrobial sus-
ceptibility patterns of these pathogens over several years,
from 1983 and 1989–2008. The study aimed to: (i) clarify
whether laboratory susceptibility testing is still worthwhile;
(ii) clarify whether the recommended treatment regimes
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need to be modiﬁed; and (iii) determine the most appropri-
ate agents for empirical therapy.
Materials and Methods
Bacterial strains
The 469 investigated strains of M. hominis (n = 290) and
ureaplasmas (n = 179) were nonduplicate isolates from the
urogenital tracts of adults collected prospectively during
1983 (when only M. hominis strains were available) and
1989–2004 (when both species were available), in Schleswig-
Holstein, north Germany. After isolation on selective growth
media and identiﬁcation by conventional biochemical meth-
ods, followed by the growth inhibition test [18] using speciﬁc
antisera as previously described [2], isolates were stored at
)70C in modiﬁed Hayﬂick‘s liquid medium (B) (for myco-
plasmas) and modiﬁed Shepard¢s Broth (S) (for ureaplasmas)
[2]. Isolates were tested with the same batch of drugs at the
same time and under the same conditions to maintain com-
parability. Results from routine testing were also obtained
from isolates collected during 2005–2008 (M. hominis,
n = 74; ureaplasmas, n = 226).
Antimicrobial agents
The antimicrobial agents used were doxycycline (DOX) and
azithromycin (AZM) (both from Pﬁzer, Karlsruhe, Germany),
minocycline (MIN) (Wyeth-Pharma, Mu¨nster, Germany), tet-
racycline (TET) (Gru¨nenthal, Aachen, Germany), clarithromy-
cin (CLR) (Abbott, Wiesbaden, Germany), erythromycin
(ERY) (Durachemie, Mu¨nster, Germany), josamycin (JOS)
(Mack, Illertissen, Germany), roxithromycin (ROX) and
oﬂoxacin (OFX) (Hoechst Marion Roussell, Frankfurt,
Germany), clindamycin (CLI) (Pharmacia & Upjohn, Erlangen,
Germany) and ciproﬂoxacin (CIP) (Bayer, Leverkusen,
Germany). Each antimicrobial agent was prepared according
to the manufacturer’s instructions at a stock concentration
of 1600 mg/L and stored at )70C before use; 0.9% NaCl
was used as a diluent for all of the drugs.
Antimicrobial susceptibility testing
Antimicrobial susceptibility was determined by the standard
agar dilution method by using modiﬁed A7-agar medium [19]
as previously described [8]. Agar plates containing two-fold
serial dilutions of antibiotics (range 0.001–16 mg/L) and anti-
biotic-free control plates were inoculated with a bacterial
suspension (approximately 105–106 CFU/mL) in S or B broth
[2] with a multipoint inoculator (Titertek; Flow Laboratories,
Meckenheim, Germany) [8]. The inoculated plates were incu-
bated anaerobically at 37C and read after 2 days under a
stereo-microscope (WILD M3; Wild Heerbrugg, Switzerland)
at ·16 and ·40 magniﬁcations. The reference type strain of
M. hominis PG 21 was included in each test. The MIC was
deﬁned as the lowest antibiotic concentration that com-
pletely inhibited the development of visible growth on the
agar plates and was determined in duplicate for each isolate.
Because no speciﬁc breakpoints have been established for
mycoplasmas and ureaplasmas, the tentative breakpoints
used for susceptible (S), intermediate (I) and resistant (R)
strains were the MIC interpretive standards (mg/L) recom-
mended by the CLSI (formerly NCCLS) for Enterobacteria-
ceae (for CIP, OFX, DOX, MIN and TET) and for
Staphylococcus spp. (for AZM, CLR, ERY, JOS, ROX and
CLI). These breakpoints were (S/I/R): for CLI, £0.5/1–2/‡4;
for CIP, £1/2/‡4; for AZM, CLR, JOS, ROX and OFX, £2/4/
‡8; for ERY, £0.5/1–4/‡8; and for DOX, MIN and TET, £4/8/
‡16 [20].
Antimicrobial susceptibilities of isolates from 2005 to 2008
(n = 300) for DOX, CIP, ERY and CLR were determined rou-
tinely by the E-test method, according to the manufacturer’s
instructions (AB Biodisk, Solna, Sweden). To estimate the
absolute level of MICs, the values were rounded up to the
next highest two-fold dilution when necessary.
Statistical analysis
The Mann–Whitney U-test was used for statistical analysis of
MIC values. The chi-square test was used to compare the
rates of susceptible and resistant strains to different antibiot-
ics. p <0.05 was considered statistically signiﬁcant.
Results
Antimicrobial effectiveness
MICs of the various antibacterials are shown in Table 1.
DOX was the most active tetracycline against ureaplasmas
and M. hominis (MIC90 of 1 and 8 mg/L, respectively). TET
and MIN showed two-fold higher MICs and, similar to DOX,
were eight-fold more active against ureaplasmas than myco-
plasmas. Signiﬁcantly more M. hominis (approximately 10–
13%) than ureoplasmas (approximately 1–3%) were resistant
to tetracyclines. OFX was effective against both species
(>95% susceptibility), and was signiﬁcantly more active than
CIP (70.3% of M. hominis and 35.2% of ureoplasmas were
susceptibile) (p <0.0001).
JOS was the only macrolide active against M. hominis. CLR
and JOS were the most potent macrolides (MIC90 of 0.5 mg/
L) against ureaplasmas; CLR was signiﬁcantly more active
than JOS and DOX (p <0.0001) and JOS was more active
than DOX (p 0.004). ERY had the lowest activity (MIC90 of
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8 mg/L) against ureaplasmas like clindamycin which was the
most potent drug against M. hominis.
Cross-resistance
A total of 17.9% (52/290) M. hominis strains were resistant
to at least one tetracycline, with 36.5% (19/52) of the
isolates showing multiple resistance; the level of cross-resis-
tance varied in the range 55.3–93.1%.
Tetracyclines showed signiﬁcantly lower cross-resistance
with OFX (0–2.6%) than with CIP (10.5–18.2%) (Fig. 1a);
approximately half the strains (44.8–55.3%) were inhibited by
£1 mg/L CIP. No cross-resistance was detected between
TABLE 1. In-vitro activity of tetracyclines, macrolides, clindamycin and ﬂuoroquinolones against 469 human isolates of genital
Mycoplasma and Ureaplasma spp.
Antimicrobial agent
Mycoplasma hominis (n = 290) Ureaplasma spp. (n = 179)
MIC (mg/L)
% resistant strains
MIC (mg/L)
% resistant strainsMIC50 MIC90 GM MIC50 MIC90 GM
Doxycycline 0.125 8 0.28 10.0 0.25 1 0.27 1.1
Minocycline 0.5 16 0.83 13.1 0.5 2 0.46 2.8
Tetracycline 0.5 16 0.87 11.4 1 2 0.74 2.8
Josamycin 2 4 1.27 3.4 0.25 0.5 0.22 1.7
Clarithromycin >16 >16 >16 99.0 0.125 0.5 0.16 4.5
Azithromycin >16 >16 >16 98.6 0.5 2 0.50 7.3
Roxithromycin >16 >16 >16 98.3 1 4 0.90 5.6
Erythromycin >16 >16 >16 95.9 2 8 1.87 20.7
Clindamycin 0.25 0.5 0.23 0.0 2 8 1.70 42.5
Oﬂoxacin 1 2 0.80 1.7 1 2 0.86 1.7
Ciproﬂoxacin 1 2 1.03 7.9 2 4 1.38 16.2
GM, geometric mean of MIC (mg/L); %, percentage of strains resistant by CLSI (2007) criteria and as mentioned in the Materials and methods.
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FIG. 1. Cross-resistance rates for Myco-
plasma hominis (a) and Ureaplasma spp. (b)
isolates to selected antibacterials such as
doxycycline (DOX), tetracycline (TET),
ciproﬂoxacin (CIP), oﬂoxacin (OFX),
erythromycin (ERY) and azithromycin
(AZM). Additional drug abbreviations are
provided in Tables 2 and 3. *Resistant iso-
lates to at least one tetracycline. aIncluding
OFX-resistant (n = 9) and -intermediate
(n = 5) M. hominis isolates. bAntibacterials
with no detectable intermediate suscepti-
bility (MIN, minocycline; CLR, clarithro-
mycin; azithromycin) not included in the
ﬁgure.
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tetracyclines and CLI, which showed the greatest potency,
inhibiting all these strains at £1mg/L (MIC90, 0.5mg/L)
(Fig. 1a).
CIP-resistant isolates were resistant to tetracyclines in
17.4–26.1% of strains and resistant to JOS in 30.4%. Isolates
inhibited by ‡4 mg/L OFX were susceptible to tetracyclines
(71–100%), CLI (79%) and JOS (71%); CIP had poor activity
(approximately 43% susceptibility).
Overall, 23.5% (42/179) of ureaplasma isolates were resis-
tant to at least one macrolide. The cross-resistance between
ERY and tetracyclines varied in the range 2.7–13.5% (Fig. 1b).
ERY-resistant isolates were susceptible to tetracyclines
(81–89%), JOS (89.2%) and OFX (86.5%) but not to CIP (19%
susceptibility). A signiﬁcantly higher level of cross-resistance
was detected between all the macrolides and ERY (70–100%).
Tetracyclines, macrolides (except ERY) and OFX were more
or less effective against CIP-resistant strains, inhibiting 86.2–
96.6%, 69–93.1% and 79.3% of the strains, respectively; JOS,
DOX and MIN had the highest efﬁciency (MIC90 of 1–2 mg/L)
and the lowest rate of cross-resistance. ERY was ineffective
(55.2% cross-resistance; MIC50/90 of 8/>16 mg/L) (Fig. 1b).
Susceptibility proﬁles over the test period
A signiﬁcant increase in tetracycline MIC90 was seen among
M. hominis isolates collected during 1989–2004 compared to
those collected in 1983 (Table 2). During the three periods
1983 (47 isolates), 1989–1996 (126 isolates) and 1997–2004
(117 isolates), the changes in resistance were: resistance to
DOX rose from 0% to 9.5% (p 0.064) to 14.5% (p 0.013);
resistance to TET rose from 2.1% to 11.9% (p 0.092) to 14.5%
(p 0.043); resistance to MIN rose from 0% to 15.9% (p 0.008)
to 15.4% (p 0.01); resistance to CIP rose from 0% to 4% to
15.4% (p 0.005); and resistance to OFX rose from 0% to 0.8%
to 3.4%. A two-fold increase in MIC90 for CLI and CIP and
reduced susceptibility towards JOS with a resistance of 8.5%
was observed in 1997–2004. The rate of resistance to DOX
in M. hominis isolates during 2005–2008, determined by the E-
test was 13.5% (MIC50/90 of 0.125/16 mg/L) and to CIP was
13.3% (MIC50/90 of 1/4 mg/L) (data not shown).
Ureaplasmas showed reduced susceptibility to all the clas-
ses of antibiotics during the studied period, leading to an
increase in MIC geometric means (Table 3). The MIC90
increased two-fold for some antibacterials during 1997–2004.
Signiﬁcantly diminished susceptibility was seen with DOX (p
0.002), TET (p 0.003), macrolides [CLR and ROX
(p <0.001), JOS (p 0.002), and AZM (p 0.007)], CIP
(p <0.0001) and OFX (p <0.001); the difference was not sig-
niﬁcant for ERY (p 0.151). However, it should be noted that
a high percentage of isolates (44.8–51.1%) were inhibited at
high concentrations of ‡4 mg/L ERY through the studied
period. A signiﬁcant increase in resistance (p 0.003) was
observed only for CIP (from 5.7 to 26.1%), whereas resis-
tance to ERY remained approximately the same (19.5% and
21.7%). Resistance to DOX and CLR remained low
(approximately 1.2%; MIC50/90 of 0.25/1.0 mg/L and 3.2%;
MIC50/90 of 0.125/0.5 mg/L, respectively) during 2005–2008;
TABLE 2. Susceptibility proﬁles of Mycoplasma hominis (n = 290) isolates collected during 1983 (n = 47), 1989–1996 (n = 126)
and 1997–2004 (n = 117)
Druga Year
Cumulative % of isolates inhibited by MIC (mg/L)b
GM of MICs (mg/L)£0.008 0.015 0.03 0.06 0.125 0.25 0.5 1.0 2.0 4.0 8.0 16 >16
DOX 1983 – – – 8.5 57.5 100 – – – – – – – 0.16
1989–1996 – 0.8 4.8 15.9 54.8 76.2 77.8 84.1 84.9 86.5 90.5 95.2 100 0.30
1997–2004 – 0.9 11.1 22.2 48.7 72.7 79.5 79.5 80.3 83.8 85.5 94.9 100 0.33
TET 1983 – – – – 6.4 10.6 34.0 93.6 97.9 97.9 97.9 97.9 100 0.78
1989–1996 – – 0.8 1.6 4.0 14.3 53.2 82.5 85.7 88.1 88.1 88.9 100 0.95
1997–2004 0.9c 1.7 3.4 9.4 16.2 26.5 53.9 76.1 82.9 82.9 85.5 88.9 100 0.81
MIN 1983 – – – – 6.4 19.2 34.0 53.2 70.2 97.9 100 – – 1.14
1989–1996 – 4.0 8.7 13.5 21.4 39.7 50.8 60.3 73.0 78.6 84.1 88.9 100 0.85
1997–2004 – – 2.6 9.4 33.3 45.3 58.1 68.4 77.8 80.3 84.6 87.2 100 0.72
JOS 1983 – – – – 2.1 6.4 27.7 51.1 80.9 100 – – – 1.25
1989–1996 – – – – 4.8 12.7 22.2 55.6 80.2 100 – – – 1.19
1997–2004 – – 0.9 6.0 9.4 14.5 24.8 41.9 67.5 91.5 99.2 99.2 100 1.37
CLI 1983 – – – 6.4 31.9 85.1 100 – – – – – – 0.21
1989–1996 – 0.8 4.0 14.3 27.8 61.1 95.3 100 – – – – – 0.24
1997–2004 – 1.7 6.8 18.8 35.9 67.5 88.9 96.6 100 – – – – 0.22
OFX 1983 – – – – – 2.1 36.2 95.7 100 – – – – 0.79
1989–1996 – – – – – 7.2 37.3 89.7 93.7 99.2 100 – – 0.83
1997–2004 – 3.4 6.0 7.7 8.6 12.8 36.8 75.2 94.9 96.6 96.6 96.6 100 0.78
CIP 1983 – – – – – – 8.5 83.0 100 – – – – 1.06
1989–1996 – – – – 2.4 7.1 27.0 69.8 96.0 98.4 99.2 99.2 100 1.01
1997–2004 – – 1.7 2.7 6.8 10.3 30.8 65.8 84.6 96.6 97.4 97.4 100 1.04
GM, geometric mean; DOX, doxycycline; TET, tetracycline; MIN, minocycline; JOS, josamycin; CLI, clindamycin; OFX, oﬂoxacin; CIP, ciproﬂoxacin; –, not detected.
aMIC50 and MIC90 of macrolides, azithromycin, clarithromycin, erythromycin and roxithromycin (not included) were >16 mg/L (Table 1).
bThe MIC50 (underlined) and MIC90 (bold) values of antibacterials against Mycoplasma (M.) hominis are indicated.
cMIC was 0.004 mg/L.
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ERY-resistance was 19% (MIC50/90 of 1.0/8 mg/L) during
2005–2008, which was comparable with results from earlier
years (data not shown).
Discussion
In the present study, different antibacterials showed different
levels of activity against these mycoplasmas and ureaplasmas.
The majority of both M. hominis and ureaplasmas were most
sensitive to OFX (approximately 95–97%), followed by tetra-
cyclines (approximately 82–88% and 96–97%, respectively)
and JOS (approximately 75 and 98%). Most were resistant to
CIP (approximately 8% and 16%). Previous studies reported
a similar susceptibility to JOS for both species (96.2% and
94.1%) and an extremely higher resistence rate to OFX
(41.2 % and 58.4% [21] compared to us (1.7%) and to the
results obtained by Be´be´ar et al. (3%) [6]. A lower sensitiv-
ity to JOS (79.2%), for ureaplasmas isolated in Athens, and a
weak effectiveness for M. hominis has been reported recently
[1]; OFX and CIP were mainly inactive, although these
authors only tested 26 M. hominis isolates and by the com-
mercially available Mycoplasma test [1].
Compared with our results, Singapore M. hominis strains
(n = 28) showed reduced susceptibility to TET but greater
susceptibility to CIP and CLI [22]. Extremely high sensitivity
to DOX and TET has been reported for M. hominis isolates
in Israel [23]. Tetracycline resistance in M. hominis and
ureaplasmas varies geographically, ranging from 10–40%
[4,11]. These regional differences might be the result of
variations in antimicrobial exposure in different patient popu-
lations [4,6]. This emphasizes the need for local surveillance
of antimicrobial resistance in these species in order to guide
empirical treatment. However, susceptibility testing of these
bacteria is not routinely carried out, a situation exacerbated
but the increasing use of molecular methods for their detec-
tion. On the basis of the results obtained in the present
study, we recommend the use of tetracyclines, especially
DOX, as well as OFX for treatment of genital mixed infec-
tions with M. hominis and ureaplasmas. The newer quinol-
ones, levoﬂoxacin (LVX) and moxiﬂoxacin (MXF), which
have good in vitro activity against both M. hominis (MIC90 of
0.5–1.0 and 0.03–0.06 mg/L, respectively) and ureaplasmas
(MIC90 of 0.5–1.0 and 0.25–0.5 mg/L), superior to that of
OFX [4, 7, 12, 24, Krausse R, Schubert S, unpublished data],
could also be considered. CIP could be used for empirical
treatment of mono-infection with M. hominis; CLI and JOS
are alternatives because CLI had the greatest potency against
M. hominis and no activity against ureaplasmas [11,25], and
JOS was the only effective macrolide against M. hominis, as
noted in previous studies [7,8,26]. M. hominis is intrinsically
resistant to ERY and other 14- and 15-membered
TABLE 3. Susceptibility proﬁles of Ureaplasma spp. (n = 179) isolates collected during 1989–1996 (n = 87) and 1997–2004
(n = 92)
Drug Year
Cumulative % of isolates inhibited by MIC (mg/L)a
GM of MICs
(mg/L)£0.008 0.015 0.03 0.06 0.125 0.25 0.5 1.0 2.0 4.0 8.0 16 >16
DOX 1989–1996 – 5.8 9.2 21.8 42.5 65.5 92.0 97.7 97.7 97.7 98.9 98.9 100 0.20
1997–2004 – – 1.1 9.8 19.6 51.1 82.6 93.5 96.7 96.7 98.9 100 – 0.35
MIN 1989–1996 2.3b 2.3b 5.8 11.5 27.6 40.2 73.6 87.4 89.7 95.4 95.6 97.7 100 0.39
1997–2004 – – 1.1 4.4 15.2 37.0 63.0 81.5 93.5 96.7 97.8 98.9 100 0.54
TET 1989–1996 1.2 1.2 4.6 5.8 17.2 37.9 54.0 77.0 92.0 96.6 96.6 96.6 100 0.57
1997–2004 – – – 5.4 9.8 13.0 32.6 64.1 88.0 95.7 97.8 98.9 100 0.96
JOS 1989–1996 – – 3.5 17.2 58.6 86.2 87.4 93.1 95.4 96.6 96.6 96.6 100 0.20
1997–2004 – – – 5.4 33.7 71.7 94.6 97.8 100 – – – – 0.24
CLR 1989–1996 1.2 9.2 21.8 42.5 77.0 83.9 88.5 88.5 88.5 90.8 90.8 90.8 100 0.15
1997–2004 – – 1.1 10.9 55.4 81.5 98.9 100 – – – – – 0.18
AZM 1989–1996 2.3 2.3 6.9 9.2 28.7 50.6 80.5 85.1 85.1 85.1 85.1 85.1 100 0.48
1997–2004 – – 3.3 8.7 15.2 30.4 54.4 82.6 100 – – – – 0.52
ROX 1989–1996 1.2b 4.6 6.9 11.5 13.8 25.3 44.8 79.3 90.8 90.8 90.8 92.0 100 0.68
1997–2004 – – – 2.2 5.4 13.0 26.1 47.8 88.0 97.8 98.9 98.9 100 1.16
ERY 1989–1996 1.2 6.9 11.5 12.6 16.1 20.7 28.7 39.1 55.2 80.5 86.2 87.4 100 1.45
1997–2004 – – – 2.2 7.6 10.9 15.2 21.7 48.9 78.3 93.5 96.7 100 2.38
CLI 1989–1996 1.2b 3.5 4.6 5.8 10.3 16.1 27.6 51.7 71.3 87.4 94.3 96.6 100 1.20
1997–2004 – – 1.1 4.4 9.8 14.1 19.6 27.2 44.6 69.6 91.3 93.5 100 2.37
OFX 1989–1996 – – 2.3 3.5 18.4 27.6 33.3 82.8 96.6 96.6 96.6 96.6 100 0.69
1997–2004 – – 2.2 3.3 5.4 6.5 15.2 60.9 96.7 100 – – – 1.07
CIP 1989–1996 2.3b 2.3b 4.6 8.1 10.3 12.6 25.3 54.0 94.3 95.4 96.6 96.6 100 0.94
1997–2004 – – – – 1.1 5.4 7.6 17.4 73.9 95.7 100 – – 1.98
GM, geometric mean; DOX, doxycycline; MIN, minocycline; TET, tetracycline; JOS, josamycin; CLR, clarithromycin; ROX, roxithromycin; AZM, azithromycin; ERY, erythro-
mycin; CLI, clindamycin; OFX, oﬂoxacin; CIP, ciproﬂoxacin; –, not detected.
aThe MIC50 (underlined) and MIC90 (bold) values of antibiotics against Ureaplasma spp. are indicated.
bMIC was 0.001 mg/L.
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macrolides, whereas Ureaplasma spp. is naturally resistant to
lincosamides such as CLI [4,10,15–17].
The most potent antibacterials against ureaplasmas were
CLR, JOS and DOX, as previously reported [4,8,26]. CIP
proved to be inactive, as reported previously [1,9], whereas
OFX exhibited good activity. AZM was effective as well, with
signiﬁcantly better activity than OFX and TET, as in previous
studies [7,9]. Recent studies reported equal activity for DOX
and JOS, but a poor activity for CLR, AZM and ERY [1].
Other studies, investigating a large number (n = 100) of
clinical isolates from different geographical regions, reported
two-fold higher MICs for AZM compared to our studies
[25]. Waites et al. [4] noted a four-fold lower MIC90 for ERY
and AZM and very low values for CLR. ERY is the most
commonly used macrolide for treating ureaplasma infections,
especially in pregnant women or neonates. However, the
high MIC of this antibiotic against this commensal pathogen
suggests that ERY is no longer the ﬁrst choice for treatment
of such infections, at least in our region. Thus, susceptibility
testing is recommended for this drug before use. CLR and
JOS or OFX could be used as alternatives, but not CIP
(approximately 20% susceptibility). This strategy may not be
transferable to other countries, such as Greece or Turkey,
because of the poor activity of CLR and OFX [1,21]. A high
percentage of our isolates (‡91%) inhibited by ‡4 mg/L ERY,
were susceptible to these drugs.
The frequency of ERY-resistant ureaplasmas varies signiﬁ-
cantly between studies [1,4,21,27]. The activity of macro-
lides, especially ERY, is markedly affected by acidic pH [4,7],
and this might partially explain the controversial results. The
medium used in the present study had a higher pH (6.5) than
that usually used (6.0) for ureaplasmas, and was unlikely to
have affected the ERY MICs [7].
Differences in susceptibilities have been reported between
the two Ureaplasma spp., Ureaplasma parvum (the most fre-
quently isolated from clinical specimens) and Ureaplasma ure-
alyticum and within the 14 distinct serovars [9,10,27,28].
However, the data are limited and conﬂicting. Unfortunately,
comparison cannot be made in the present study because
our isolates were not serotyped. In our region, ureaplasmas
resistant to tetracyclines are rare, as recently reported
(approximately 3%) [14]; thus, tetracyclines, especially DOX,
continue to be the ﬁrst choice for treating infection with
these bacteria. DOX-resistant isolates were often accompa-
nied by resistance to macrolides and CIP, but not to OFX.
Therefore, OFX may be a therapeutic option in the manage-
ment of ureaplasmal infections when tetracyclines cannot be
used or macrolide resistance is a local problem.
Signiﬁcant cross-resistance was detected between all the
macrolides and ERY (up to 100%). CLR-resistant ureaplasmas
were mainly resistant to all other macrolides and quinolones,
so these drugs cannot be considered as an alternative; in
these cases, DOX, which exhibited the lowest rate of cross-
resistance, could be used. CIP showed limited cross-resis-
tance with OFX; thus, OFX could also be used as a second
alternative to tetracyclines. JOS could be used for CIP-resis-
tant strains, but not vice versa; OFX-resistant ureaplasmas
were all resistant to CIP, as previously reported [6].
Similar to previous studies [23], we found a high
frequency of cross-resistance between tetracyclines for
M. hominis; in these cases, OFX, CLI, or JOS may be consid-
ered. TET-resistant strains have been reported to have
similar susceptibility to quinolones as the TET-susceptible
strains [7,24,29]; this is in disagreement with our results,
which showed that TET-resistant strains showed a signiﬁ-
cantly diminished susceptibility to quinolones.
Differences in antibacterial sensitivity were observed over
the study period with more susceptible strains isolated in the
earlier years. Resistance to CIP increased over the study per-
iod for both species. M. hominis has become more resistant
to tetracyclines and ﬂuoroquinolones over the years 1989–
2004, with no changes in 2005–2008. A continuous rise in
resistance, in M. hominis, to tetracyclines was reported previ-
ously [13,14]. There was a signiﬁcant increase in MICs of all
agents against ureaplasmas; however, there was no increase
of resistance (except for CIP). DOX- and CLR-resistance
remained low and unchanged during 2005–2008, as previously
reported [14]. Generally, in our region, ureaplasmas have
become signiﬁcantly more resistant to CIP over the last few
years and have shown very high ERY-resistance.
The susceptibility of ureaplasmas and M. hominis to anti-
bacterials in different regions is difﬁcult to compare because
of different test methods, different breakpoints and a lack of
standardization [4,7,30]. As far as we know, this is the ﬁrst
study to extensively analyse the resistance and cross-resis-
tance to different classes of antibacterials, against a large
number of clinical isolates of M. hominis and ureaplasmas
over a long time period in Germany.
In conclusion, DOX is still the drug of ﬁrst-choice for
ureaplasmal infections and may be used for co-infection with
M. hominis. CLI is very active against M. hominis and may be
used as an alternative to tetracyclines. CLR and JOS exhib-
ited an excellent efﬁcacy against ureaplasmas; JOS is also
active against mycoplasmas and may be used as an alternative
to tetracyclines and ERY and in mixed infections, especially
in pregnant women and neonates. OFX and the newer
ﬂuoroquinolones, LVX and MXF, are effective against both
species and may be used in cases of tetracycline- and
ERY-resistance. However, local in-vitro susceptibility testing is
recommended, especially for ERY and CIP.
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